Tumor-treating Fields Do Not Negatively Affect Health-related QoL
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Glioblastoma
Sorafenib Plus Temsirolimus Demonstrates Limited Benefit in Glioblastoma
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Tumor-treating Fields Improve Glioblastoma Outcomes
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
Tumor Treating Fields May Improve Glioblastoma Outcomes
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
Rindopepimut Not Associated With Prolonged Survival in Glioblastoma
At the preplanned interim analysis, the study was discontinued for futility.
Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
FDA Grants Orphan Drug Status to SurVaxM for Glioblastoma
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
Glioblastoma Survival Rates May Improve With New Immunotherapeutic Approach
New immunotherapeutic approaches, such as dendritic cell vaccination, may be effective for treating this rare brain cancer, which is associated with dismal survival rates.
- Loading...
Loading...
Next post in Brain Cancer
Loading... 
Loading...